drugset / Trial / NCT00796224

Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media

NCT00796224

Phase 2 Completed 38 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to determine the pharmacokinetics (PK), safety and clinical response following a single dose of either 30 mg/kg IR (Immediate Release) or 60 mg/kg ER (Extended Release) formulation in pediatric subjects 6 months to 6 years of age inclusive.

Timeline

Start
2008-12
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azithromycin Small molecule 30 mg/kg Oral
Comparator Azithromycin Small molecule 60 mg/kg Oral

Indications